Inclisiran for Cardiovascular Disease (V-INITIATE Trial)

"That is correct, the online information does show that this clinical trial is still looking for participants. The first posting was on June 25th 2021 and there have been subsequent updates to the page, with the latest one being on October 17th 2022. In total, they are trying to get 444 people involved at 40 different hospitals or clinics."

"Out of the 11 ongoing studies investigating Inclisiran, 10 are currently in Phase 3. Most of these live clinical trials are being conducted in Ciudad de Mexico, but Inclisiran is also being studied at 1414 other locations around the world."

"Inclisiran is considered safe according to our team's 3-point scale. This is due to the fact that Phase 3 trials have provided some data affirming the drug's efficacy as well as multiple rounds of data supporting its safety."

"There have been 11 clinical trials for Inclisiran since 2018, with the most recent one concluding earlier this year. These studies took place in 588 cities and 52 countries across the globe. The first study, sponsored by Novartis Pharmaceuticals, completed its Phase 3 drug approval stage in 2018."

"While primary hypercholesterolemia is the most common reason to use Inclisiran, this medication can also help patients with diet-controlled hypercholesterolemia and atherosclerotic cardiovascular diseases."

"That is right, the clinicaltrials.gov website has information which says that this research project is looking for more participants. The first posting was on 6/25/2021 and there have been updates as recently as 10/17/2022. So far, 444 people have signed up across 40 different locations."

"Presently, this clinical trial is being conducted at 40 different sites. The locations are situated in Marshfield, Weston and Hershey as well as other cities. If you elect to participate in this research study, it would be advantageous to select the clinic nearest your location to reduce travel requirements."

"The primary objective of this trial, which will be measured over a period of 330 days, is the change in LDL cholesterol levels from baseline. Additionally, this trial will also measure secondary outcomes including changes in VLDL cholesterol and apoB levels, as well as the intensity of lipid-lowering therapy (i.e. whether the dose is increased, decreased, or remains unchanged) over the same time period."